DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Herpes Zoster (Shingles) - Pipeline Review, H1 2017" report to their offering.
This latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.
Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 3, 1, 1, 6 and 1 respectively.
Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Report Coverage
- Herpes Zoster (Shingles) - Overview
- Herpes Zoster (Shingles) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Herpes Zoster (Shingles) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
- Astellas Pharma Inc
- Beijing Minhai Biotechnology Co Ltd
- ContraVir Pharmaceuticals Inc
- Epiphany Biosciences Inc
- Foamix Pharmaceuticals Ltd
- GeneOne Life Science Inc
- GlaxoSmithKline Plc
- Merck & Co Inc
- NAL Pharmaceuticals Ltd
- NanoViricides Inc
- SK Chemicals Co Ltd
- TSRL Inc
For more information about this report visit http://www.researchandmarkets.com/research/q64t3d/herpes_zoster